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Abstract
PURIFICATION OF A NOVEL MID-REGION FRAGMENT OF PARATHYROID
HORMONE-RELATED PROTEIN AND EVIDENCE OF ITS SECRETION BY
THREE DIFFERENT CELL TYPES
Despite presumptive evidence for extensive posttranslational processing, little is
known of the native secretory forms of Parathyroid Hormone-related Protein (PTHrP),.
To identify these forms, PTHrP species were purified from conditioned medium and cell
extracts from three cell types: human renal carcinoma (SKRC-1) cells, human
keratinocytes, and rat insulinoma cells transfected with the cDNA for PTHrP (1-141)
(RIN-141 cells). Amino-terminal and mid-region species were immunoaffinitypurified
using anti-PTHrP (1-36) and anti-PTHrP(37-74) columns respectively. Immunopurified
species were further resolved by reversed-phase high performance liquid chromatography
(RP-HPLC) and identified using region-specific immunoassays. Purified species were
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
amino acid sequencing and immunofluorescence studies.
RIN-141 and SKRC-1 cells secreted at least three amino-terminal PTHrP species
as well as a novel mid-region fragment. Analysis by SDS-PAGE and amino acid
sequencing indicated that the RIN-141 mid-region fragment begins at residue 38 of the
cDNA-predicted sequence and is approximately 70 amino acids in length. Comparison of
the RP-HPLC elution patterns suggests that SKRC-1 cells and keratinocytes secrete a
similar if not identical mid-region fragment. Immunohistochemical studies revealed a
secretory granular pattern for the mid-region species and a Golgi pattern for aminoterminal species.
It follows from these studies that 1) three cell lines secrete multiple secretory
forms of PTHrP, including a novel mid-region fragment, 2) Arg’7 serves as a monobasic
endoproteolytic processing site in the PTHrP biosynthetic precursor; 3) PTHrP (1-36) is
an authentic secretory form of PTHrP; and 4) the mid-region fragment appeares to be
packaged into secretory granules.

I Introduction

1. Discovery
The discovery of parathyroid hormone-related protein (PTHrP) as the cause of
humoral hypercalcemia of malignancy (HHM) occurred some 60 years after serum
calcium concentrations were first discovered to be elevated in many patients with cancer.
Early studies in the 1930's and 40's first indicated that the high serum calcium
concentrations were almost always associated with skeletal metastases and thus were
inferred to result from active bone resorption by tumor cells.28 In 1941, Fuller Albright
adumbrated that a humoral mechanism might explain the occurrence of hypercalcemia in a
patient with renal cell carcinoma with a solitary skeletal metastasis.1. This notion
remained unsubstantiated for 15 years until two series of patients in the 1950's were
published. In these studies, a humoral form of hypercalcemia was demonstrated in all
subjects as defined using two major criteria: 1) hypercalcemia occurred in the absence of
radiologically evident skeletal metastases, and/or 2) hypercalcemia was corrected by the
removal of the primary tumor mass.17,71 A 1966 series reviewed 50 patients with
malignancy-associated hypercalcemia who met these criteria for HHM. Those patients
tended to have squamous, renal, urothelial and gynecologic tumors. In contrast, patients
with local osteolytic hypercalcemia (LOH) due to skeletal invasion by their tumors
typically suffer from multiple myeloma or metastatic breast carcinoma. It was also
observed that the syndrome of HHM was far more common than previously had been
thought.47
Increasing interest in the search for the mediator(s) of HHM in the 1960's and 70's
lead to the consideration of vitamin D-like sterols, prostaglandin E (PGE), and parathyroid
hormone (PTH) and its precursors. The earliest studies focused on plant-derived vitamin
D analogs (phytosterols) found in the circulation of several patients with breast carcinoma
and hypercalcemia.27 However, further investigation proved that these sterols lacked the
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potency to cause hypercalcemic effects in the concentrations measured in plasma.29 In
1970, PGE2 was implicated as a cause of hypercalcemia when studied in animal tumor
models.42 Studies which followed in humans in the following decade, however, proved
that PGE as a source of hypercalcemia is extremely rare.56
Albright had originally suggested PTH as the most likely mediator of HHM. The
idea of‘ectopic hyperparathyroidism’ gained some weight when the use of a first
generation PTH radioimmunoassay (RIA) demonstrated elevated PTH levels in patients
with certain tumors.4 In the 1970's, wide use of the PTH RIA documented detectable (but
not elevated) concentrations of PTH in serum and PTH immunoreactivity in tumors. 3 70
However, controversy grew as to whether PTH was actually the cause of hypercalcemia in
these patients. The concentration of PTH measured in these patients varied widely and, in
most cases, though detectable by sensitive assays, were disproportionately low, as would
be expected as the natural physiologic reaction to high serum calcium produced by some
other cause. Over the ensuing decade, it became clear that PTH is not the usual cause of
HHM. Recently, a modern two-site immunoradiometric assay (IRMA) has clearly
demonstrated that circulating PTH is suppressed or unmeasurably low in patients with
HHM.7,62 There are several examples in the literature of ectopic PTH production by
tumors, but these are exceedingly rare and tend to result from unusual tumor types.62 94 114
In 1980 and 1981, several independent groups published studies of renal calcium,
phosphate and most importantly, nephrogenous cyclic adenosine monophosphate
(NcAMP) excretion in large series of patients with malignancy-associated
hypercalcemia.25,45,79'89 Two groups were defined. One group comprised 80% of the
patients and displayed characteristics which came to define HHM. These include
increased excretion of NcAMP, increased calcium excretion, decreased circulating
l,25(OH)2D levels and normal to decreased PTH levels. These patients suffered primarily
from squamous, renal and urothelial tumors and had a low incidence of bony metastases.
The remaining 20% had decreased NcAMP and a high incidence of skeletal metastases.
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These patients were hypercalcemic due to their skeletal metastases, primarily from breast
and hematologic tumors.
Next, Goltzman29 in 1981 found PTH-like bioactivity in the circulation of patients
with HHM, not present in patients with LOH, using a sensitive cytochemical bioassay for
PTH. However, the circulating bioactive material was larger than PTH on gel filtration.
In addition, these patients demonstrated an uncoupling of bone turnover with increased
osteoclastic bone resorption and decreased osteoblastic activity, unlike the coupled bone
turnover which is stimulated by high levels of native PTH. Thus, patients with HHM were
found to have a circulating factor in their serum with both “PTH-like” and “PTH-unlike”
characteristics.
This PTH-like protein was eventually purified simultaneously by three groups, who
each managed to overcome the protein's low abundance by employing a PTH-sensitive
adenylate cyclase assay for the detection of the factor in conditioned medium from a
squamous cell carcinoma,58 a renal cell carcinoma,95 and from squamous cell and breast
tumor extracts.9. The isolated protein, parathyroid hormone-related protein (PTHrP), was
found by N-terminal sequencing to posses 13 N-terminal amino acids highly similar to
those of PTH. The amino acid sequence distal to this region revealed a unique sequence
unlike any other known peptide. The amino acid sequence of this new peptide revealed an
explanation for its “PTH-like” and “PTH-unlike” qualities. As will be discussed, the
amino-terminal PTH-like sequence corresponds to the receptor-activating region of PTH.
The remaining unique sequence explains the PTH-unlike characteristics.
Using an oligonucleotide probe designed using the N-terminal sequence data from
the isolated protein, the cDNA for PTHrP was isolated and the gene found to be located
on chromosome 12.54'96 The gene encoding PTH itself is located on chromosome 11.
This pair of chromosomes is thought to have arisen long ago from an ancestral
duplication. The location of the the PTH and PTHrP genes on chromosomes 11 and 12,
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together with their shared intron-exon structure, raises the likelihood that thse genes form
two members of a small gene family.
It it now widely acknowledged that PTHrP is the principal cause of HHM First,
using PTHrP RIAs and a two-site PTHrP IRMA, elevated levels of PTHrP have been
found circulating in the serum of patients with HHM.9,10 Second, synthetic and
recombinant PTHrP peptides have been shown to reproduce all of the features of the
syndrome, as shown in animals as well as tissues, organs or cells in
vitro. 19’32>33,4o,58,68,69,88,91,107,112 T^ird, passive immunization with PTHrP antiserum reverses
HHM in animals. ’1,46 These and other studies have established that PTHrP is both
necessary and sufficient to cause HHM, with rare exceptions already noted.

2. The PTHrP Gene and mRNA Species
In contrast to the relatively simple organization of the PTH gene, the gene for
PTHrP (fig. 1) reveals a high degree of complexity, with at least three promoters, seven
exons, and three alternative 3’ splicing patterns. The ancestral similarity of the two genes
is apparent in the shared structure and organization of the middle exons of the PTHrP
gene when compared to the three exons of PTH gene. While the PTH gene is expressed
exclusively in the parathyroid gland, the PTHrP gene has been found to be expressed at

Fig. 1. The organization of the human PTHrP gene. Exons are indicated by boxes designated bv a Roman
numeral; white—5' noncoding; black—coding; grey—3’ noncoding. Tl, T2 and T3 indicate upstream and
downstream transcription initiation sites respectively; consensus TATA boxes are found upstream of both
sites. Other transcription initiation sites lying between Tl and T3 may also be used (dashed line exonic box
and arrow). Positive numbers denote the position of nucleotides encoding amino acids in the mature peptide
and negative numbers the position of nucleotides encoding amino acids in the prepro region of the peptide.
Alternate mRNA splicing options are indicated by arrows connecting coding exons. Modified from
Halloran.30
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low levels in many tissues throughout the body. In fact, growing evidence is pointing to
an almost purely paracrine/autocrine role for PTHrP.

Systemic humoral or endocrine

effects of PTHrP appear to be found only in the pathologic condition seen in cases of
HHM.
The human gene sequence encodes three mRNA species which correspond to
resultant peptides with different carboxy termini (1-139), (1-141), and (1-173) (see fig. 3).
Little is known about the splicing patterns employed for these three messages among
different tissues. Recent work has put forth the possibility of tissue-specificity of PTHrP
transcripts and processing of their respective protein products.110 Interestingly, the 3’
untranslated regions are rich in mRNA instability motifs comprising multiple repeated
patterns of the sequence ‘AUUUA.’ Such motifs lead to the rapid degradation of those
mRNA species which contain them. These motifs are commonly present in genes
controlling cellular proliferation and differentiation. These motifs encoded in the 3’
untranslated region of PTHrP mRNA species are highly conserved from mouse to man
and are the only downstream elements conserved in the PTHrP gene among species.
Since the transcription rates of the PTHrP gene are in general comparable to those of
more abundant mRNA species, and since the half-lives of PTHrP mRNAs are short, these
sequences may appear to account for the low levels of PTHrP found in most tissues.
Furthermore, the existence of these sequences implies an autocrine/paracrine role for the
protein product.29'39,53,54,82,96,111 A thorough discussion of the structure and regulation of
the PTHrP gene is beyond the scope of this paper. However, a picture is emerging of a
widely expressed, locally-acting regulatory peptide. The marked conservation among
species suggests that its actions are crucial to normal development. This has been borne
out by the findings of Karapalis et. al.,39 who have shown that the homozygous disruption
of the PTHrP gene in mice has lethal consequences.
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3. Gene Expression and Regulation
Use of molecular biologic and sensitive immunochemical techniques has
demonstrated the expression of the PTHrP gene in a wide array of adult tissues (skin,
bone marrow, stomach, brain, kidney, heart, vascular smooth muscle, skeletal muscle,
lung, pancreatic islets, parathyroid, adrenal, testis, ovary, uterus, lactating mammary gland
and placenta) as well as fetal tissues (brain, liver, heart, lung, intestine, skeletal muscle,
chorioallantoic membrane, and yolk sac)/0 The study of PTHrP gene regulation has
illuminated a large number of factors which affect its transcriptional activity. The
following is an overview of some of these areas of investigation.
Several hormones have been implicated in this regulation. For instance, studies in
vitro have shown that transcriptional activity is reduced by increasing levels of
glucocorticoids and l,25(OH)2D3 in a human thyroid C-cell line/’5'50 Activity in an
osteoblast-like cell line is stimulated, however, by epidermal growth factor (EGF) and
phorbol esters. Since EGF is mitogenic in these cells, it has been proposed that PTHrP
may act as a paracrine mediator of the mitogenic response in these cells.22'44’75
Studies in vivo have also demonstrated hormonal modulation of PTHrP
expression. Studies with rats have shown that post-partum suckling in the first two weeks
stimulates the lactating mammary gland to increase PTHrP production abruptly, and that
when suckling ceases, PTHrP drops back to low levels.8,108 This response was shown to
result from changes in prolactin levels.97 Studies with pregnant rats have also produced
evidence that estrogens stimulate the production of PTHrP message in the rat uterus,100 as
do estrogen analogs such as tamoxifen.99
The syndrome of HHM has been seen as a complication not only of solid tumors
but also of adult T-cell leukemia caused by the human T-cell leukemia virus type 1
(HTLV-1).41 Studies have shown a correlation between infection with the HTLV-1 virus
and expression of the PTHrP gene, and suggest that viral factors may direct PTHrP
production in infected cells.59,60

The expression of PTHrP has also been shown to be responsive to stretch. One
group examined rats with unilateral pregnancy, where the developing fetus is located in
only one horn of a bifid uterus. This can occur naturally or by surgical manipulation.
Investigators detected dramatic elevations of PTHrP mRNA only in the gravid horn.98
This group’s work has shown that a biomechanical stimulus causes the sysnthesis of
PTHrP. Further research has shown that PTHrP mRNA in the rat urinary bladder rises
with increasing bladder volume.109 As will be discussed later, PTHrP has been shown to
relax smooth muscle in various systems.57'83’84'101’104 It may be, therefore, that PTHrP
plays an autocrine/paracrine modulatory role in accommodation of intraluminal volume in
hollow viscera and vascular tissue.

4. The Peptide and its Regulation
Multiple forms of PTHrP are synthesized and secreted by cells. As described
earlier, the gene encodes three different precursor proteins which are translated from three
alternatively spliced mRNA transcripts (fig. 3). Each of these three mRNA species
encodes a putative 36 amino acid 'prepro' sequence, followed by three mature protein
isoforms, each of which is identical in the initial 139 amino acids, but differs in its carboxyl
terminus (1-139, 1-141, 1-173). PTH, by comparison, is synthesized as one isoform
comprising 84 amino acids.
The primary structure of PTHrP may be divided into several regions (fig. 2). The
N-terminal sequence from amino acids 1-13, with 70% homology to the corresponding
amino acids in PTH, is the signal transduction activating region and confers PTH-like
biologic activity. The sequence from amino acids 14-34 is divergent from PTH yet,
surprisingly, is necessary for binding to the PTH receptor. The region spanning 35-111 is
highly conserved among species: the 70 amino acid stretch between residues 38-108 in
the human sequence differs by only two amino acids from its counterparts in the rat and
mouse, and by 11 amino acids from that in the chicken. ’0'87 Such a degree of conservation
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Fig. 2. Structural and functional domains of PTHrP (1-141).

See text for details. Modified from

Stewart and Broadus.8

surpasses that of such important peptides as insulin and growth hormone, suggesting a
crucial, yet undetermined physiological role. This region is rich in potential posttranslational processing sites as is discussed below in section 1.8. Finally, the C-terminal
sequences diverge greatly among species. Though it has been speculated that these
regions may confer tissue specificity, this is yet to be determined.6'
The secondary and tertiary structure of PTHrP (1-34) has been modeled using the
circular dichroism model and compared to PTH (1-34). This model predicts similar
structures for N-terminal PTHrP and PTH with two a-helices (the binding core) and a
connecting hydrophilic bridge (activating region).16,30
There are several regulatory mechanisms controlling the availability of the peptide.
In addition to transcriptional controls mentioned above, steady state mRNA levels appear
to be regulated by mRNA stability. In addition, post-translational processing steps such as
proteolytic cleavage, glycosylation and amidation, may play a significant role in PTHrP
regulation and function, and is discussed further in section 1.8.

The existence of multiple regulatory mechanisms at the gene, mRNA and protein
levels support the building impression of a diverse set of local control mechanisms over
the availability of PTHrP. This adds more weight to the idea of PTHrP as a locallysecreted and locally-acting autocrine/paracrine hormone, which is regulated close to its
sites of action.

5. PTHrP Receptors
The mechanism of action of PTHrP, at least as it acts in HHM, has been shown to
be through PTH receptors in bone and kidney. Indirect evidence of this was inferred in
early studies in which patients were found to have increased nephrogenous cAMP
excretion despite low PTH levels.89 In fact, as already discussed, this was the basis of
early renal cortical adenylate cyclase bioassays for PTHrP. Direct support was gained
when radioligand binding experiments demonstrated that synthetic PTHrP (1-34) could
compete equally effectively with PTH (1-34) for binding to PTH receptors in bone and
kidney.95 In fact, once the PTH receptor was cloned, both PTH and PTHrP were shown
to bind with equal affinity to this single receptor.1
The fact that PTHrP and PTH can act via the same receptor in bone and kidney
does not rule out the possibility that PTHrP might have its own unique receptors in other
tissues. The hypothesis has been put forth that such receptors may reside in nonclassical
PTH target tissues. Pharmacologic amounts of PTH have been shown to cause relaxation
in vascular smooth muscle,18,102 uterus,84 gastric smooth muscle,57 and tracheal smooth
muscle,115 yet there is no evidence that PTH acts on these tissues at physiologic levels.
These studies, however, have shown equal potencies of PTH and PTHrP on these tissues.
The search for a unique PTH receptor has only begun. Preliminary findings strongly
indicate that unique PTHrP receptors do exist, for example, in keratinocytes and
pancreatic islet cells.24,64 The study of the secretory forms of the protein has demonstrated
that receptors for non-amino-terminal secretory forms of PTHrP are likely to exist as well.
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This paper will present evidence of a secreted fragment which does not include the Nterminal PTH-like sequence; any physiologic effect of this novel peptide would likely
result from action on a novel receptor.
6. HHM and the Mechanism of Action of PTHrP
HHM is the most common paraneoplastic syndrome, most often occurring in
squamous cell and renal cell carcinomas.9,10,25,47,89 In addition, about 30% of breast
cancer-associated hypercalcemia is caused by PTHrP production rather than by skeletal
metastases. 37 Lymphomas associated with HTLV-1 infection also produce PTHrP 59,60
Finally, tumors which traditionally produce hypercalcemia by direct skeletal invasion, such
as myeloma, may also, on occasion, meet the criteria for HHM with increased serum
PTHrP and urinary NcAMP levels.9,10,25,89
In patients with HHM, the high PTHrP concentrations have been shown to
increase serum calcium by action on bone and kidney. Yet there remain three unexplained
differences between hyperparathyroidism and FIHM. First, in the bone of patients with
FIHM, unlike the increased coupled bone turnover seen in hyperparathyroidism, there is
decreased osteoblastic activity uncoupled from highly increased osteoclastic bone
resorption. It is known that osteoclasts lack PTH receptors, and that PTH acts on
osteoblasts, which in turn stimulate osteoclastic activity. Though PTHrP may indeed act
in this way, it is yet to be discovered how the differential between the effects of PTH and
PTHrP are created. There may be PTHrP receptors on other cells present in the marrow
which may in turn stimulate osteoclastic activity.78 On the other hand, osteoblasts, though
few in number, may still be the target of action and have the potency to effect such a
response from osteoclastic cells. There is little data to support such theories and they
remain speculative.
Second, in the kidney, PTHrP appears to act, as does PTH, on PTH receptors
causing an increase in NcAMP and a decrease in the renal phosphate threshold/0 Animal
studies using short synthetic peptides have shown that PTHrP increases calcium
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reabsorption in the kidney.20,74'81'85 However, patients with HHM have been shown to be
relatively hypercalciuric compared to those with primary hyperparathyroidism.
Third, there is also a discrepancy in vitamin D production. l,25(OH)2D levels in
patients with HHM are reduced compared to those found in patients with
hyperparathyoidism.25,89 If all of the actions of PTHrP are exclusively mediated via the
PTH receptor, the differences between hyperparathyroidism and HHM remain difficult to
explain. In addition, the nature of the actual secreted forms of the peptide and the
mechanism whereby they act have yet to be elucidated. Investigation of the structure of
these native forms and their physiology may reveal specific mechanisms of action which
account for such discrepancies.

7. The Roles of PTHrP in Normal Physiology
Since PTHrP is nearly ubiquitous in human tissues, the protein has been
implicated, logically, in a multitude of roles in normal physiology. Those highlighted here
are elaborated in much greater detail elsewhere. '0 PTHrP, found in abundance in
keratinocytes, has been found to stimulate an increase in intracellular calcium without
stimulating adenylate cyclase, and investigations continue as to a possible role as a
mitogen and/or differentiation factor.64 As already mentioned, PTHrP has been found to
act as a smooth muscle relaxant in the vasculature,18'102 myometrium,84 stomach,'7
bladder,109 and trachea.11' In the kidney, PTHrP has been shown to display growth-factorlike effects on renal fibroblasts, and stimulates the proliferation of renal carcinoma
cells. '0'87 In contrast, among lymphocytes PTHrP inhibits proliferation, and is
manufactured only by transformed or activated cells.55 In the pancreas, PTHrP binds to
islet cells and stimulates an increase in intracellular calcium.24
There has been a tremendous amount of research on PTHrP and its role in fetal
and neonatal physiology. Fetal calcium levels are maintained at a higher level than found
in maternal serum. While fetal PTH is very low, PTHrP is produced in a variety of fetal
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tissues and the placenta.M) Studies have accumulated indicating an important role for
PTHrP in fetal-maternal calcium regulation. A sheep placental model experiment showed
that the fetal parathyroid makes PTHrP which stimulates calcium transport across the
placenta.76 Similar studies showed that PTHrP promotes magnesium placental transport
as well as calcium.51,76 Studies with thyroparathyroidectomized lambs showed that
PTHrP's effects on the fetus include stimulating fetal bone remodeling, and increasing
serum calcium, renal calcium reabsorption, urinary pH, and circulating l,25(OH)2D
concentrations.14
Another example of interest is the role of PTHrP in lactation, since there are
particularly high levels of the peptide in breast milk. Suckling produces a rise in prolactin
levels, followed by a sharp rise in PTHrP and its secretion into milk. One study showed
increasing levels of calcium in the breast milk corresponded with increasing levels of
secreted PTHrP.48 It may be acting as a local paracrine factor within the breast to
stimulate calcium transport into milk. It could also play a role in calcium homeostasis in
the neonate. Once ingested, the protein could be taken up intact by pinocytosis to act
until the infant's PTH axis is fully active. One study showed that neonates who were
formula-fed had a steeper decline in calcium levels than those who were breast-fed 8 The
diverse areas of investigation are proving that the role of PTHrP in normal physiology is
truly far-reaching.

8. Posttranslational Protein Processing
From the cDNA-predicted PTHrP amino acid sequences, it is known that PTHrP
contains several classic endoproteolytic processing sites. The peptide contains many
clusters of basic residues (arginine (R), and lysine (K)) from singlets to quintuplets (fig. 3).
Endoproteolytic processing of prohormone precursors has been studied extensively,
including in mammalian systems.23,49 The processing signals best known are dibasic and
tetrabasic sites, which are cleaved in mammals by a family of proteins which act as
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prohormone-conversion enzymes. An example is furin, a Golgi-based enzyme acting at
neutral pH, which prefers the site of cleavage [RX{R/K}R], where the third residue may
be either an arginine or lysine, and X represents any amino acid. Furin has been found to
process many protein precursors including albumin, von Willebrand factor, growth factors,
and complement

Another class of mammalian processing enzymes includes PC-1 and PC-

2. These are packaged with their substrates into secretory granules and are activated in
these granules by a fall in pH and a rise in calcium. These prefer dibasic sites of cleavage
(commonly KR or less often KK) and are involved in, for example, the processing of
proopiomelanocortin (POMC) and proinsulin. More recently, PC-4, PC-5 and PC-6 have
been described, but little is known about their function.
In addition to those preferring dibasic and tetrabasic sites, there are also monobasic
cleaving enzymes which prefer a single R residue (less often K). A number of
requirements regarding the surrounding sequence guide the enzymatic cleavage at these
sites.2'1'49 Monobasic residues have been discovered to be the site of cleavage in atrial
natriuretic peptide (ANP), pancreatic polypeptide, somatostatin, gastrin, dynorphin A,
growth hormone releasing hormone (GHRH), and cholecystokinin (CCK).
Finally, there are two potential sites for carboxyterminal amidation within the
cDNfi-Predicted PTHrP flmino Bcid Sequences
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PTHrP amino acid sequence. The enzyme peptidyl alpha amidating monooxygenase
(PAM) is known to be active in the processing of many prohormones including amelanocyte stimulating hormone (a-MSH), oxytocin, antidiuretic hormone (ADH),
corticotrophin releasing hormone (CRH), and thyroid releasing hormone (TRH). ’ ’ ’ ’
The consensus sequence consists of [X-gly-dibasic], where X denotes the residue which is
ultimately amidated, and the adjacent glycine donates the amino group. The protein is first
cleaved by a furin-like enzyme which cuts at the carboxyl end of the dibasic residues.
Then a carboxypeptidase cleaves off the basic residues leaving X-gly, which is then
amidated by PAM. The two amidation consensus sites within PTHrP are at prolines at
position 86 or 94 in the sequence (fig. 3), which would yield a proline amide at the
carboxyl terminus. PAM is known to have a widespread tissue distribution which overlaps
in most cases with that of PTHrP. It is notable that many of the PAM substrates are made
more active by amidation, leaving open the possibility that the amidation of PTHrP may
significantly alter its biologic activity, strengthening the importance of identifying the
actual secreted forms.
Once it was observed that the cDNA-predicted amino acid sequence contained
multiple potential processing sites, it was suspected that PTHrP would be
posttranslationally processed in some way. It is known that for PTHrP, as is the case with
many other secreted peptides, the 36 amino acid 'prepro' sequence which allows passage
into the endoplasmic reticulum is cleaved cotranslationally by signal peptidase.65 In
addition, the 'pro' sequence ending with KR at the -2 and -1 positions is known to be
cleaved, since the mature peptide starts with an alanine at position +1. By analogy to
other secreted peptides, this sequence is most likely cleaved in the Golgi apparatus or
secretory granule. The purpose of this 'pro' region in PTHrP, and in other peptides, has
been speculated to relate to intracellular targeting or stability, but may also serve some
unknown function.23,49-105

In addition, there is evidence that PTHrP is glycosylated

In keratinocytes, sugar

residues have been found on an N-terminal secretory form of the peptide.1116 Since there
are no N-glycosylation consensus sites (Asn-X-Ser/Thr), it is assumed to be Oglycosylated. This O-glycosylation may play a role in intracellular trafficking and stability,
or may influence the plasma half-life or biologic potency as is the case for erythropoietin,
leutinizing hormone (LH), human chorionic gonadotropin (hCG), and thyroid stimulating
hormone (TSH).38'61’73’80
The findings presented in this study provide the first evidence that PTHrP is
endoproteolytically cleaved within the cell and secreted in distinct fragments. Moreover,
proof is offered that a monobasic processing site utilizing the arginine at position 37 of the
amino acid sequence signals cleavage of the protein. The novel peptide isolated from
three different cell lines begins at amino acid 38 and is approximately 60-70 amino acids in
length. This highly conserved sequence promises to play a crucial role in cellular
physiology throughout human tissues.
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II Materials and Methods

1. Cell Lines
The human renal carcinoma line SKRC-1 was provided by Dr. Neil Bander at the
Memorial-Sloan Kettering Cancer Center. These cells were selected for study as an
example of a naturally-occurring cell line which produces PTHrP and which causes HHM
in vivo. These cells were grown in Eagle's minimal essential medium supplemented with
10% fetal bovine serum, 200 IU/ml penicillin, and 1% L-glutamine, as described in detail
previously.10’ Rat insulinoma (RIN 1046-38) cells were provided by Dr. Michael Appel at
the University of Massachusetts. These cells were selected for transfection and
overexpression of PTHrP since they faithfully process a variety of other neuroendocrine
preprohormones. A PTHrP cDNA fragment encoding amino acids 1-141 of the human
sequence34 was ligated into the retroviral vector pLJ which contains a neomycin selectable
marker.42 RIN cells were then transfected using the lipfection method, and stable
transfectants were selected using the antibiotic G148. These cells, henceforth referred to
as "RIN-141" cells, were grown in RPMI containing 10% fetal bovine serum, 200 IU/ml
penicillin, and 1% L-glutamine. Each cell line was maintained at 37°C in a humidified
atmosphere of 5% CO2, 95% air. Human neonatal keratinocytes were grown in primary
culture, and medium was harvested from these cells as previously described.106

2. Stability of 125I-PTHrP( 1-141) in the Presence of SKRC-1 and RIN-141 Cells
Prior studies had shown106 that addition of protease inhibitors to growth medium in
concentration sufficient to prevent degradation of PTHrP following secretion was
deleterious to the health of the cells and their fidelity in processing. Accordingly, the
stability of PTHrP exposed to confluent cells in culture without protease inhibition was
examined using 125I-PTHrP( 1-141), as described previously.106 Briefly, recombinant
PTHrP( 1-141) (provided by Dr. Glenn Hammonds, Genentech, S. San Francisco, CA)
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was iodinated with Na 125I (Amersham Corp.) using the Enzymobead method (Bio-Rad).
125I-PTHrP( 1-141) was added to both SKRC-1 and RIN-141 cells grown to confluence in
24-well plates. At the time points described in fig. 4, medium containing 12:T-PTHrP( 1141) and its degradation products was removed from the wells, combined with protease
inhibitors as described below, and analyzed by SDS-PAGE and autoradiography. These
studies demonstrated that the majority of PTHrP( 1-141) remained undegraded at 90
minutes; this 90-min. time point was therefore selected for harvesting "protease-protected"
medium as described below.

3. Preparation of Conditioned Medium
SKRC-1 cells, RIN-141 cells and human epidermal keratinocytes were each grown
to confluence in 40 150-cm2 flasks. Six ml of medium was added to each flask of
confluent cells for exactly 90 min. Medium was then harvested and fresh medium was
added to each of the cultures. This procedure was repeated up to five times in a 24 hr.
period until 6 liters of SKRC-1, 5.5 liters of RIN-141 and 1 liter of keratinocyte 90 min.
conditioned-medium were collected. This medium was immediately chilled and
supplemented with protease inhibitors, which included (final concentrations) aprotinin
(20|ig/ml) (Boehringer-Mannheim), bacitracin (lOOpg/ml) (Sigma), chymostatin
(50pg/ml) (Boehringer-Mannheim), EDTA (3mM) (Sigma), leupeptin (15pig/ml)
(Boehringer-Mannheim), pepstatin A (45pg/ml) (Bachem Bioscience, Philadelphia, PA),
and phenylmethanesulfonyl fluoride (45pg/ml) (Sigma). This protease-protected medium
was stored at -20°C until further use.

4. Immunoaffinitv Purification of PTHrP Fragments
Six liters of SKRC-1, 5.5 liters of RIN-141 and 1 liter of keratinocyte 90-min.
conditioned medium were applied in 250-ml aliquots to a 300-pl anti-PTHrP(l-36)
immunoaffinity column at 4°C, as described in detail previously.106 To ensure complete
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removal of amino-terminal PTHrP species, the medium that flowed through the column
was applied to the anti-PTHrP(l-36) affinity column a second time. This second "flow
through" medium, determined by immunoassay to be free of amino-terminal PTHrP, was
then applied in 100-ml aliquots to a 300 pil anti-PTHrP(37-74) immunoaffinity column.
The PTHrP species adherent to the affinity columns were eluted with 5 ml of 200 mM
glycine HCL, pH 2.5. The acid eluates from each column were further purified using RPHPLC on Vydac (Separations group, Hesperia, CA) 218TP104 analytical C-18 columns
using gradients of 28-38% and 15-33% acetonitrile in water containing 0.1%
trifluoroacetic acid as described in figs. 3-5 and 8 respectively.

5. PTHrP Immunoassays
PTHrP immunoreactivity in medium and in column fractions was detected using
three previously described PTHrP immunoassays (see fig. 1, lower panel). The PTHrP(l36) RIA employs a polyclonal anti-PTHrP(l-36) antibody at a titer of 1:1500 and human
36Tyr-PTHrP(l-36) amide as standard and radioligand.10 It recognizes both the (1-36)
fragment and the full-length PTHrP species with a sensitivity of 50 pM. The PTHrP(3774) RIA employs a polyclonal sheep anti-PTHrP(37-74) antibody at a titer of 1:2,000, and
a synthetic human PTHrP(37-74) as standard and radioligand. It recognizes both the (3774) fragment and the full-length PTHrP species with a sensitivity of 10 pM.11

Lastly, the

PTHrP immunoradiometric assay (IRMA) recognizes only those species of PTHrP which
include both the (1-36) and (37-74) PTHrP epitopes; it uses an affinity-purified rabbit
anti-PTHrP(37-74) as capture antibody, a second iodinated affinity-purified rabbit antiPTHrP(l-36) as signal antibody, and a synthetic human PTHrP(l-74) as standard. It has a
sensitivity of 1 pM.10

19

6. Extraction ofSKRC-1 and RIN-141 Cells
SKRC-1 and RESf-141 cells were grown to confluence in 10 150-cm2 flasks each.
The cells were first rinsed with phosphate-buffered saline, and then 3 ml of 4M guanidine
isothiocyanate, 8% (v/v) 2-mercaptoethanol, containing 50 mM Tris-HCl, pH 7.5, and 25
mM EDTA, were added to each flask for 5 min. on ice. The cells were then scraped into a
centrifuge tube, ice-cold ethanol was added to final concentration of 30% ethanol, and this
ethanol-guanidinium extract was chilled at 4°C for 10 min. Following centrifugation at
16,000 x g for 10 min. at 4°C, the supernatant was removed and dialyzed using a
Spectrapor-3 membrane (3,000 molecular weight cut-off) against 16 liters of water at 4°C
over 48 hrs. The dialyzed extract was centrifuged at 16,000 x g for 10 min. at 4°C and
the supernatant collected and resolved using RP-HPLC as described in fig. 5.

7. Immunofluorescence
Cells were plated onto coverslips (Fisher), grown until 75% confluent, and then
fixed with 2% paraformaldehyde at room temperature for 45 min. The cells were rinsed
with 10 mM phosphate-buffered saline, 0.2% bovine serum albumin, and then
permeabilized for 15 min. with 0.05% saponin in lOmM phosphate-buffered saline, 0.2%
bovine serum albumin. Affinity-purified rabbit antibodies to PTHrP regions (1-36) and
(37-74)10 108 were then added to the permeabilized cells for 2 hours at room temperature.
After rinsing, anti-rabbit fluorescein isothiocyanate-conjugated goat F(ab')2 fragments
(Tago Immunologicals, Burlingame, CA) were added to the cells at a 1:200 dilution in a
darkened moisture chamber for 1 hr. For insulin immunohistochemistry, anti-insulin
guinea pig antibodies (ICN Biomedicals, Inc., Costa Mesa, CA) were added as primary
antibody and were detected using an anti-guinea pig fluorescein isothiocyanate-conjugated
antibody (Organon Teknika, Inc., Durham, NC) at a 1:200 dilution. Golgi staining was
performed with the mouse monoclonal antibody 53FC32 (provided by Dr. A. Danoff and
Dr. R. Angeletti at the Albert Einstein College of Medicine) and then detected using anti-
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rabbit, rhodamine-B-conjugated goat F(ab)2 fragments (Tago). Cells were then preserved
in p-phenylenediamine and photographed using a Zeiss Axiophot fluorescent microscope.

8. Analysis of Purified Species
Tricine-SDS-PAGE and western analysis were performed using 10-18% gradient
gels. Transfer to immobilon nylon membranes (Millipore, Bedford, MA) was performed
using standard methods, 5% bovine serum albumin as blocker, and polyclonal rabbit antiPTHrP(l-74) antibody at a titer of 1:200 as primary antibody, and a silver-enhanced, goldlabeled second antibody method for detection (Janssen Products, Olen, Belgium).
Dot blots of synthetic peptides PTHrP(l-36), (37-74), and (1-74) were performed
by placing 10 x lpl drops directly onto nylon membranes, allowing the paper to dry
between drops, to final amounts of 1, 10, 30 and 100 ng for each peptide. Blotting was
then performed in an identical manner as described for western blots.
Size-exclusion HPLC was performed using SW 300 and I 125 protein pak columns
connected in series. The mobile phase was 30% acetonitrile, 70% H20 and 0 1%
trifluoroacetic acid. The flow rate was 0.7 ml/minute.

9. Amino Acid Sequencing
Amino Acid sequencing was performed in the William Keck Protein and Nucleic
Acid Chemisrty Facility at Yale University using an Applied Biosystems model 407A gas
phase sequenator.

10. Procedures Performed by This Author
This author performed the harvesting of conditioned media from both RIN-141
and SKRC-1 cells, immunoafFinity purification of mid-region species, RP-HPLC and size
exclusion HPLC, radioimmunoassay, tricine-SDS-PAGE, western blot, and dot blot of the
various PTHrP species. Harvesting of medium and immunopurification of the amino-
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terminal species, their analysis by RIA and RP-HPLC, and immunohistochemistry was
performed by Dr. Neil Soifer. Degradation studies and immunopurification of PTHrP
species from cell extracts performed by Mr. Terrence Wu.
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III Results

1. Stability of PTHrP in Conditioned Medium
The purified species of PTHrP from conditioned media must be a valid
representative of the secreted form of the peptide. Previous studies have shown the
instability of secreted PTHrP in plasma72 and in culture.108 To demonstrate the stability of
PTHrP species in SKRC-1 and RIN-141 cell culture conditions, exogenous iodinated
PTHrP( 1-141) was incubated with these cell lines for the times indicated in figure 4.
Panel A shows the degradation of PTHrP in the presence of cultured keratinocytes
described previously,106 where the initial single 23-25 kDa band is broken down to smaller
components over time. SKRC-1 cells are much less active in degrading PTHrP {panel B),
and RIN-141 cells show little or no degradation over time {panel C). From this data it
was determined that the secreted species of PTHrP from these cell lines would not suffer
significant degradation by 90 minutes of incubation, thus purification of secreted species
was performed from serial collections of 90 minute medium.

Fig. 4. Degradation of iodinated,
recombinant PTHrP(l-141)
after exposure to confluent cells
under non-protease-protected
conditions. Radiolabeled PTHrP
was analyzed by SDS-PAGE and
autoradiography after collection at
the time points indicated. STD
indicartes intact peptide prior to
cell exposure. A, cultured human
epidermal keratinocytes described
previously.106 B. cultured SKRC1 cells. C, cultured RIN-141 cells.

Hours
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2. Immunoaffinitv Purification of Secreted PTHrP Species

a. SKRC-1 Cell Line, amino-terminal species
Six liters of 90 minute conditioned medium was harvested under proteaseprotected conditions. This initial media contained approximately equimolar amounts of
PTHrP (1-36) and PTHrP(37-74) species by radioimmunoassay (Table 1). After
extraction with the anti-PTHrP(l-36) affinity column, virtually all of the 1-36 activity was
stripped from the media, as measured by 1-36 RIA. The acid eluates from the PTHrP (136) affinity column were further purified by RP-HPLC and examined by 1-36 RIA and 174 IRMA (fig. 5, top panel). SKRC-1 media contained three major amino-terminal
species. Peak I contains both 1-36 and 1-74 immunoreactivity, and migrated in a position
analogous to that of the glycosylated amino-terminal peptide isolated previously from
keratinocytes.106 Peak II contains only 1-36 activity and thus represents a smaller aminoterminal fragment. Peak III contains both 1-36 and 1-74 activity, yet elutes with a very
different retention time than does peak I, and thus may represent a larger amino-terminal
fragment distinct from previously isolated species.

b. SKRC-1 Cell Line, mid-region species
The SKRC-1 conditioned medium, after being stripped of PTHrP(l-36)
immunoactivity, was found to retain the same concentration of PTHrP(37-74)
immunoactivity as had the initial medium, indicating the presence of a mid-region, non¬
amino-terminal PTHrP species in the medium. This medium, already stripped of
PTHrP(l-36) immunoactivity was then affinity-purified using an anti-PTHrP(37-74)
antibody column, and resolved by RP-HPLC in the same fashion as were the aminoterminal species (fig. 5, bottom panel). The SKRC-1 medium contained a previously
unrecognized, mid-region PTHrP peptide which eluted as a single peak with a unique
retention time, earlier than that of any other species identified to date. In
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Table 1. Immunoreactive PTHrP species in conditioned medium. Quantities of PTHrP present in SKRC1- and RIN-141-conditioned medium and cell extracts. “90-min conditioned medium'’ and “guanidinium
extract” refer to immunoreactive quantities available prior to purification. The PTHrP concentration was
significantly higher in conditioned medium than in cells. Numbers in parentheses indicate the recovery of
immunoreactivity given as a percent of the original immunoreactivity. PTHrP recovery after purification was
less than 40%.

90-min conditioned medium
1-36
37-74
1-74
N-terminal HPLC peak III
1-36
1-74
Mid-region fragment
37-74
Guanidinium extract
1-36
37-74
1-74

SKRC-1 (pmol)

RIN-141 (pmol)

1,158 (100)a
870 (100)
324 (100)

1,788 (100)b
2,822 (100)
468 (100)

a pmol/6 liters
b pmol/5.5 liters

107
25

(9.2)c
(7.7)

28
2.2

(2)d
(0.5)

cd pmol/peak

330

(37.9)

750

(26)

2e
1.3
0.85

1.7f
0.85
0.7

e 1 pmol/flask

addition, this peptide was present in larger amounts than were any of the amino-terminal
fragments (fig. 5; table 1).

c. Transfected RIN-141 cell line, amino-terminal species
RIN-141 conditioned medium (5.5 liters) was harvested and immunoaflfinity
purified using an anti-PTHrP(l-36) antibody column in the same manner as was the
SKRC-1 medium. The immunoactivity in the RP-HPLC purified fractions is shown in fig.
6, top panel. As in the SKRC-1 purified medium, the RIN-141 medium contained three
amino-terminal species. However, all three peaks demonstrated both 1-36 and 1-74
immunoreactivity.

d. Transfected RIN-141 cell line, mid-region species
As had been the case with SKRC-1 media, the RIN-141 conditioned media,
stripped of amino-terminal immunoactivity, was found to retain full mid-region
immunoactivity. This amino-terminally stripped media was further purified using an anti-
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PTHrP(37-74) antibody column as had been performed with the SKRC-1 media, and the
acid-eluates resolved by RP-HPLC. The resultant peak in (37-74) RIA activity contained
neither (1-36) RIA or (1-74) IRMA immunoactivities (fig. 6, bottom panel),
demonstrating, as was found in the mid-region SKRC-1 medium, that RIN-141
conditioned medium contains a single, non-amino-terminal fragment which elutes at an
identical retention time as does the SKRC-1 fragment. This mid-region PTHrP species is
present in much larger quantities in RIN cell medium than in SKRC-1 medium, reflecting
the overexpression of PTHrP in RIN cells.

3. PTHrP Species in Cell Extracts
Despite the demonstration of low levels of degradation of PTHrP by media
proteases, it remained of some concern that the purified species from 90 minute media
represented artifactually degraded products from a larger secreted peptide. To disprove
this possibility, cell extracts of both SKRC-1 and RIN-141 were analyzed for the presence
of intracellular PTHrP species prior to secretion. Guanidine isothiocyanate/ 6mercaptoethanol extraction was employed for its immediate protease-inactivating
property, simplicity of use and yield comparable to other methods used previously .90
Extracts were applied directly to RP-HPLC without preliminary immunoaffinity
purification. Fig. 7 shows the elution patterns for (1-36) RIA, (37-74) RIA and (1-74)
IRMA immunoactivities in SKRC-1 cells (top panel), and RIN-141 cells (bottom panel).
Multiple amino-terminal fragments are present in both SKRC-1 and RIN-141 cells prior to
secretion, most of which contain both 1-36 and 37-74 epitopes with similar elution
patterns as were demonstrated in conditioned medium.

AFFINITY-PURIFIED CONDITIONED MEDIUM
RENAL CARCINOMA
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Fig. 5. Immunoreactive PTHrP species from SKRC-l-conditioned medium. RP-HPLC chromatogram (J'me clotted
line) with retention time and elution patterns are shown at A2io. The gradient is 28-38% acetonitrile in water
containing 0.1% trifluoroacetic acid. Upper panel, amino-terminal PTHrPs. The heavy clotted line indicates (1-36)
RIA aevtivity. The thin solid line indicates (1-74) IRMA activity. Multiple species are present, with three major peaks
(I. II. and III). Lower pane/. non-amino-terminal PTHrP. A single peak is present, consisting only of (37-74) RIA
{heavy dotted line) activity.
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Fig. 6. Immunoreactive PTHrP species from RIN-141-conditioned medium. RP-HPLC chromatogram (fine dotted
line) with retention time and elution patterns are shown at A2io. Upper panel, amino-terminal PTHrPs. Multiple
species are present, with three major peaks (I, II, and III). (1-74) IRMA concentrations (thin solid tine) are represented
at 50 X actual concentrations to allow better visualization. Lower panel, non-amino-terminal PTHrP. A single peak is
present, consisting only of (37-74) RIA activity (heavy solid line). The heavy dotted line indicates (1-36) RIA activ ity.
The gradient is 28-38% acetonitrile in water containing 0.1% trifluoroacetic acid.
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Fig. 7. Immunoreactive PTHrP species from cell extracts. RP-HPLC chromatogram (fine dotted tine) with retention
time and elution patterns shown. Upper panel, SKRC-1 cell extract. Multiple amino-terminal species are present by (1 36) RIA (heavy dotted line) and (1-74) IRMA (thin solid line). Multiple (37-74) RIA (heavy solid line) immunoreactive
fragments are also present, including an early eluting peak that corresponds to the non-amino-terminal peak found in
conditioned medium. Lower panel. RIN-141 cell extract. Multiple amino-terminal and non-amino-terminal species are
present. An early eluting fragment contains only (37-74) RIA immunoreactivity (heavy solid line). The gradient is 2838% acetonitrile in water containing 0.1% trifluoroacetic acid.
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More importantly, a non-amino-terminal (37-74) immunoreactive fragment was
present within both SKRC-1 and RIN-141 cells prior to secretion. This fragment eluted in
the same position as did the corresponding peptide derived from conditioned medium
(fig s 5-7). This evidence confirms that the mid-region PTHrP is processed to its mature
form within the cell prior to secretion. As had been observed in conditioned medium, the
mid-region peptide was present at a much higher concentration in cell extracts than were
the amino-terminal fragments. The overexpression of PTHrP in RIN cells produced levels
of the peptide that were 30 times higher in RIN-141 cells than in SKRC-1 cells (Table 1).
Finally, the SKRC-1 cells contained a second non-amino terminal (37-74) immunoreactive
peak which is not present in RIN-141 cells, nor in either of the conditioned medium
preparations.

4. Analysis of the Mid-region PTHrP Fragment
a. Tricine SDS-PAGE
The mid-region fragment purified from conditioned media from the two cell lines
shown in the bottom panels of fig s 3 and 4 were analyzed by Tricine SDS-PAGE. One
hundred ng of the RIN-141 fragment and 30 ng of the SKRC-1 fragment were shown to
migrate as single homogeneous bands of approximately 7kDa each, slightly below
synthetic PTHrP(l-74) (fig.8).

Fig. 8. Tricine SDS-PAGE and silver stain
of the (37-74) immunoreactive, non-aminoterminal fragment. Lane 1. lOOjug of the
(37-74) PTHrP fragment from RIN-141conditioned medium. Lane 2, molecular
weight markers. Lane 5. lOOng of synthetic
PTHrP (1-74). molecular mass ~8.5 kDa.
Lane 4. 30gtg of the (37-74) PTHrP fragment
from SKRC-1-conditioned medium. Each
(37-74) species appears as a homogeneous
narrow band with a molecular mass ~7kDa.
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b. Western Blot
In order to confirm that the band visualized on SDS-PAGE was identical to the
mid-region PTHrP detectable by RIA, western blotting was employed. It was found that
the synthetic PTHrP(37-74) peptide itself migrates anomalously making comparison of
purified fragments to a standard (37-74) fragment impossible. In addition, the (37-74)
region, when applied to nitrocellulose paper, stains poorly with the same affinity-purified
anti-PTHrP(37-74) antibodies used in the affinity purification of these peptides, preventing
its detection by western blot of PTHrP fragments in this region. To confirm this, varying
concentrations of synthetic PTHrP(37-74) were compared in a dot blot to the same
concentrations of synthetic PTHrP(l-36) and PTHrP(l-74). The staining of the 37-74
peptide is sparse compared to the other two synthetic peptides. It was concluded that
western blotting using the available mid-region PTHrP antibody would not be useful in the
study of PTHrP processing.

c. Size-exclusion HPLC
Attempts to analyze the purified fragments by size-exclusion HPLC failed to add
any additional information as to their nature or size. Acid-eluates from the antiPTHrP(37-74) immunoaffinity column were resolved using two size-exclusion affinity
columns in series. The resultant peaks were too broad to accurately determine size of the
various fragments and were too widely overlapping to properly resolve the 37-74 RIA
curve from the 1-36 RIA curve.

d. Amino Acid Sequencing
Amino Acid sequencing of 30 pmol of the RIN-141 mid-region fragment purified
from conditioned media yielded 34 cycles of amino acid sequence identical to amino acids
38-71 of the cDNA predicted PTHrP sequence (fig. 9). Thus the amino terminus of the
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mid-region fragment secreted by RIN-141 cells begins at amino acid 38 of the cDNApredicted peptide.
Attempts to sequence 7 pmol of the mid-region fragment purified from SKRC-1
conditioned medium were unsuccessful. In order to analyze the similarity between the two
mid-region fragments, a sample of both the RIN-141 and SKRC-1 peptides was run over a
RP-HPLC column on a shallow gradient chosen for its superior resolving power. The
resultant elution patterns are shown in fig. 10. The SKRC-1 mid-region fragment (top
panel) and the RIN-141 mid-region fragment {middle panel) eluted at identical retention
times.
Keratinocytes are well known to produce amino-terminal PTHrP. Since we had
not previously analyzed keratinocyte-conditioned medium for the presence of this novel
mid-region peptide, protease-protected conditioned medium from keratinocytes was
immunoaffinity-purified using an anti-PTHrP(37-74) antibody column and run on the same
shallow-gradient HPLC column as the SKRC-1 and RIN-141 fragments had been resolved
in fig. 10. The bottom panel shows that a chromatographically indistinguishable mid¬
region fragment of PTHrP is indeed produced by keratinocytes. Therefore, it is likely that
all three cell types secrete a highly similar if not identical mid-region species.
cDNA position
cDNA amino acid
mid-region amino acid
mid-region position

38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56
Ala Thr Ser Glu Val Ser Pro Asn Ser Lys Pro Ser Pro Asn Thr Lys Asn His Pro
x Thr Ser Glu Val Ser Pro Asn Ser Lys Pro Ser Pro Asn Thr Lys Asn x Pro
1
2 3
4 5
6 7
8
9 10 11 12 13 14 15 16 17 18 19

cDNA position
cDNA amino acid

57 58 59 60 61 62 63 64 65 66 67 68 69 70 71
Val Arg Phe Gly Ser Asp Asp Glu Gly Arg Tyr Leu Thr Gin Glu

mid-region amino acid
mid-region position

Val x Phe Gly Ser Asp Asp Glu Gly x Tyr Leu Thr x Glu
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34

Fig. 9. Amino Acid sequence of the non-amino-terminal, mid-region immunoreactive fragment from
RIN-141-conditioned medium. This sequence is compared with the cDNA-predicted amino acid sequence, x
refers to amino acids that could not be identified with complete accuracy.
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Fig. 10. Elution patterns of the (37-74) immunoreactive, non-amino-terminal fragments in conditioned
medium from three different cell lines. RP-HPLC chromatogram {fine dotted line) is shown using a 15-33%
gradient of acetonitrile in water with 0.1% trifluoroacetic acid. Upper panel. SKRC-1 mid-region fragment.
Middle panel. RIN-141 mid-region fragment. Lower panel, normal human keratinocyte mid-region fragment.
(37-74) RIA immunoreactivity is indicated by the solid line.
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5. Immunohistochemical Localization of PTHrP in RIN-141 and SKRC-1 Cells
To determine the intracellular locations of the PTHrP species identified in both cell
extracts and conditioned media, SKRC-1 and RIN-141 cells were examined using
immunohistochemistry with region-specific PTHrP antibodies. Fig. 11 A and D show a
perinuclear pattern when cells are stained with anti-PTHrP(l-36) antibodies, suggesting
that the amino-terminal PTHrP species is located primarily in the Golgi apparatus, as seen
in fig. 11, G. In contrast, cells stained with anti-PTHrP(37-74) antibodies demonstrate, in
addition to perinuclear staining, a prominent peripheral staining pattern typical of proteins
contained in secretory granules (fig. 11, B and E). RIN-141 cells stained with anti-insulin
antibodies demonstrate a similar peripheral granular staining pattern seen in fig. 11, H.
Control studies without the use of primary antibody or with excess concentration of
competing peptides display no immunofluorescence (fig. 11, C and F).
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Fig. 11. PTHrP Immunohistochemistry using affinity-purified, region-specific antibodies. A. SKRC1 cell stained with anti-PTHrP (1-36) antibody. B. SKRC-1 cell stained with anti-PTHrP (37-74)
antibody. C. SKRC-1 cell stained without the addition of a primary antibody. Similar results (not shown)
were obtained when affinity-purified antibody was added to a non-PTHrP-producing renal carcinoma cell
line. D, RIN-141 cell stained with anti-PTHrP (1-36) antibody. E. RJN-141 cell stained with anti-PTHrP
(37-74) antibody. F, RIN-141 cell stained without the addition of primary antibody. G. RIN-141 cells
stained with anti-Golgi antibody. H. RIN-141 cells stained with anti-insulin antibody.
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IV Discussion

Considering the widespread distribution of PTHrP in adult and fetal tissues and the
lethality of PTHrP gene “knockout,’’one must imagine a significant and essential role it
might play in cellular physiology. Borne out in many studies of normal physiology and
malignant cells, the theory that PTHrP acts a widespread autocrine/paracrine factor, with
growth factor and other actions, has gained general acceptance. The investigation of this
role until now has relied on the use of synthetic amino-terminal peptides manufactured
based on their homology to PTH. The low abundance of PTHrP has prevented large-scale
harvesting of the native forms for further study. Identification of the native secreted and
circulating forms would be a helpful advance in the study of the physiologic action of
PTHrP.
Study of the molecular biology of PTHrP has produced a multitude of possible
regulatory steps in the biosynthesis of the protein, such that one might predict many
alternative final peptide forms (fig s 1,3). In addition to its several mRNA species, PTHrP
has in its sequence many putative proteolytic processing sites and potential sites for Cterminal amidation and O-glycosylation. It has previously been shown that one secreted
species of PTHrP from human keratinocytes is an 18-kDa O-glycosylated amino-terminal
form of the peptide.106 These cells are useful to study since they represent a normal cell
type. However, keratinocyte studies require continuous preparation of primary cultures of
human keratinocytes. In addition, the forms secreted from these cells may differ from
those secreted by malignant cells in the syndrome of HHM, or from those produced by the
various neuroendocrine cell types which produce PTHrP, such as the pancreatic beta cell,
the pituitary somatotrope, the adrenal medulla and the CNS neuron.
Two additional cell lines, RJN-141 cells and SKRC-1 human renal carcinoma cells,
were included in this study with these considerations in mind. Both secrete PTHrP in
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relative abundance, and neither has demonstrated the propensity to degrade exogenously
added iodinated PTHrP( 1-141) as has been observed for keratinocytes (fig. 4).
Several new secretory forms of PTHrP were discovered during this study. At least
three amino-terminal species (immunoreactive with the anti-PTHrP(l-36) immunoaffinity
column) were isolated from both RIN-141 and SKRC-1 cells, most of which contained
(37-74) immunoreactivity as well. The precise structure of these N-terminal species is
currently under study.

The earliest eluting of these species from both RIN-141 and

SKRC-1 cells comigrates with the glycosylated N-terminal species isolated from human
keratinocytes. Whether these forms are indeed glycosylated has yet to be determined.
The most important discovery made in this study was the isolation of a novel mid¬
region form of PTHrP secreted by all three cell types. The existence of such a mid-region
peptide had been suggested by the recognition of cleavage sites surrounding this area in
the cDNA predicted amino acid sequence (fig.3)/0,87 The mid-region fragment, missing
the N-terminal sequence of the protein, was not recognized by the PTHrP (1-36)
antiserum and does not contain amino-terminal epitopes. It is recognized by a mid-region
PTHrP anitserum. This peptide migrates as a single peak both on RP-HPLC and SDSPAGE, is present both in conditioned medium following secretion and within cells prior to
secretion. It has an amino terminus which begins at amino acid 38 of the cDNA-predicted
PTHrP sequence
Several implications follow from these observations. First, the PTHrP biosynthetic
precursor must be cleaved at the arginine residue at position 37 in the sequence.
Proteolytic cleavage at monobasic sites, most commonly a single arginine, is a common
occurrence in protein processing as was discussed in the Introduction. Second, although
there are many serine and threonine residues in this sequence which might serve as Oglycosylation sites, all of these residues were identified in the amino-acid sequencing of the
isolated peptide from residues 38-71, and thus it is unlikely that the peptide is Oglycosylated prior to amino acid 71. This is further supported by the appearance of the
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peptide on SDS-PAGE as a sharp band (fig. 8), in contrast to the broad appearance of the
glycosylated species isolated from keratinocytes.106 Third, the estimated molecular mass is
approximately 7 kDa, which implies a length of 60-70 amino acids. This would place the
carboxy-terminus of the fragment in one of two intensely basic regions of the peptide,
amino acids 96-98 or 102-106 (fig. 3), long hypothesized to be proteolytic processing sites
for PTHrP.’0,87 Current studies are aimed at precisely defining this C-terminus of the
fragment. The low abundance of the peptide make this task extremely difficult.
Since the mid-region fragment from SKRC-1 cells was available only in small
amounts, N-terminal sequencing of this peptide was not possible. It was possible to more
precisely examine its behavior on chromatographic evaluation. The SKRC-1 fragment
migrated in an analogous position on SDS-PAGE to the mid-region fragment isolated
from RIN-141 cells, and was found to elute at a similar or identical position on RP-HPLC
on two different gradients. It is likely then, although not proven, that the mid-region
fragment isolated from SKRC-1 cells begins at position 38 of the cDNA-predicted
sequence. After simultaneously isolating mid-region fragments from these two cell lines, a
similar study of keratinocyte-conditioned medium was performed in search of a
comparable peptide secreted from these cells. One liter of protease-protected
keratinocyte-conditioned medium was first stripped of N-terminal immunoreactivity and
then examined for mid-region immunoreactivity. Human keratinocyte-conditioned
medium was shown to contain a mid-region fragment of PTHrP which is very similar if not
identical to that secreted by RIN-141 and SKRC-1 cells (fig. 10).
The fact that this mid-region fragment results from cleavage at the arginine at
position 37 lends indirect evidence that PTHrP( 1-36) is a secreted form of the peptide.
Synthetic PTHrP(l-36) has been manufactured in the past with this processing site in
mind. However, this represents the first evidence that this sequence may be an actual
secreted form of the protein.
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Much consideration went into determining whether the species collected were
secretory forms of PTHrP or merely degradation products formed after secretion into the
media. First, extensive precautions were undertaken to prevent artifactual proteolysis,
including the use of protease inhibitors and collection of 90-minute medium. Second,
degradation studies were undertaken which proved that both SKRC-1 and RIN-141 cells
display little breakdown of exogenously added iodinated PTHrP( 1-141). Third, it was
shown that cells extracted with guanidinium, which inactivates proteases, contained what
appears to be the identical mid-region fragment isolated from conditioned medium.
Finally, immunohistochemical studies indicate that the mid-region fragment localizes to
peripheral granules which are most likely secretory vesicles, whereas the N-terminal
species localizes to the perinuclear Golgi apparatus. The peripheral granular pattern is
commonly seen when staining for proteins which undergo regulated secretion, as seen in
immunohistochemical staining for insulin. These findings all support the idea that PTHrP
is manufactured in the cell as a larger precursor molecule, undergoes proteolytic cleavage
intracellularly and then is secreted as at least two separate fragments— one amino-terminal
and one non-amino-terminal species.
Since both these species are secreted from the cell, it is interesting that they
localize to different areas according to immunohistochemical staining. One might
postulate that the mid-region fragment is routed to the regulated secretory pathway,
whereas the amino-terminal fragment is routed to a constitutive secretory pathway.
However, it is possible that the different patterns of localization may result from
idiosyncratic staining problems. For instance, it may be that the amino-terminal species
does indeed reside in secretory vesicles, but the amino-terminal antibody used for staining
might not recognize the species due to folding or packaging of the peptide, or some other
post-translational modification. Further study is needed to trace the intracellular
trafficking of the various PTHrP species.
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It was mentioned in the Introduction that the mid-region of PTHrP is a very highly
conserved sequence across species. Considering that the region is flanked by proteolytic
processing sites, the conserved sequence from 38-108 is speculated to act in some crucial
role in physiology. This study has provided additional evidence that this sequence is
indeed processed into a separate fragment, and likely targeted into a regulated secretory
pathway. Moreover, this fragment is so produced by three different cell lines. In terms of
understanding the physiology of this mid-region secretory form of PTHrP, Care, et. al.15
have recently shown that a fragment of PTHrP which includes amino acids 67-86 is
capable of regulating calcium transport across the placenta. It is unknown whether the
peptide identified by Care bears the same carboxy-terminus as does that isolated in our
study. It will be interesting to determine whether the mid-region fragment we have
isolated demonstrates this calcium-regulatory property.
If the physiologic role of this new peptide is related to calcium homeostasis, this
finding could generate more insight into the action of PTHrP in HHM. This could explain
the mysterious differences in bone coupling, l,25(OH)2 vitamin D metabolism and renal
calcium handling which occur in HHM and hyperparathyroidism. In addition to action on
PTH receptors by the amino-terminal fragment of PTHrP, the mid-region fragment may
simultaneously alter calcium regulation independently and create the different biochemical
profile and bone turnover unique to HHM. On the other hand, if one makes any
comparisons of PTHrP and its processing to other protein precursors such as POMC and
their final end products, one need not invoke related actions of the resulting peptide
hormones. They may vary as widely as do ACTH, a-MSH and endorphins. More
detailed study of this mid-region fragment and its role in physiology may produce evidence
of an important molecular role in the basic function of a broad range of human tissues.
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